Skip to main content

Table 3 Dietary intake data of 459 dogs included in the study

From: Exploring the potential link between vegetable oil supplementation and adverse food reactions in dogs: a preliminary study

Category

Subcategory

%

n

All dogs

 

100

459

Diet

   

Dietary type

Commercial pet food

59.69

274

 

Maintenance diet

91.24

250

 

Veterinary prescription diet (all conditions)

8.76

24

 

Veterinary prescription diet for skin problems

6.93

19

 

Hydrolyzed veterinary prescription diet

0.73

2

 

Home-made diet

8.93

41

 

Commercial and home-made diet

31.37

144

 

Maintenance diets

95.14

137

 

Veterinary prescription diet (all conditions)

6.94

10

 

Veterinary prescription diet for skin problems

6.94

10

 

Hydrolyzed veterinary prescription diet

2.78

4

Diet changes before clinical signs onset

From commercial to home-made diet

5.01

23

 

From home-made to commercial diet

2.44

11

Main protein/carbohydrate in the diet

   

(Reported for ≥ 3 dogs)

Chicken

73.86

339

 

Rice

62.75

288

 

Beef

31.59

145

 

Fish

31.37

144

 

Lamb

5.66

26

 

Potatoes

5.66

26

 

Pork

4.79

22

 

Wheat

4.79

22

 

Turkey

3.49

16

 

Duck

1.74

8

 

Eggs

1.09

5

 

Hydrolyzed food

1.09

5

 

Dairy products

0.87

4

 

Only vegetal

0.87

4

 

Rabbit

0.65

3

Oil supplementation

 

14.16

65

Type of oil

Extra-virgin olive

70.77

46

 

Corn

10.77

7

 

Mix seeds

10.77

7

 

Olive

4.62

3

 

Sunflower

3.08

2

Amount of teaspoons of oil per ration

1

64.62

42

 

2

30.77

20

 

> 2

4.62

3

Frequency of oil supplementation

1 = A few times/year

0

0

 

2 = A few times/month

13.84

9

 

3 = A few times/week

13.31

8

 

4 = Daily

50.77

33

 

5 = Multiple times/day

23.08

15

Onset of oil supplementation/clinical signs

Supplementation before clinical signs

90.77

59

 

Supplementation after clinical signs

9.23

6

Dietary supplements containing EFA

 

2.40

11

 

Supplementation before clinical signs

18.18

2

 

Supplementation after clinical signs

81.82

9